Literature DB >> 15257708

Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires.

Danielle Canioni1, Pauline Brice, Eric Lepage, Myrna Chababi, Véronique Meignin, Bruno Salles, Luc Xerri, Pierre-Yves Péaud, Philippe Rousselot, Michel Peuchmaur, Philippe Solal-Céligny, Nicole Brousse.   

Abstract

The influence of bone marrow biopsy (BMB) histology on prognosis and management of follicular lymphomas (FL) remains controversial. A total of 390 patients with grade 1 or 2 FL were prospectively included in the multicentric Groupe d'Etude des Lymphomes Folliculaires trial and their BMB reviewed in order (i) to quantify the ratio of lymphomatous foci (LFo) area to that of BMB size (LFo/BMB), (ii) to determine the BMB patterns for a practical grading of marrow infiltration, (iii) to assess the intra- and inter-observer reproducibility of this grading and (iv) to analyse this grading on event-free (EFS) and overall survival (OS), using univariate and multivariate analyses. A total of 267 patients (68%) had BMB involvement, with inter- and intra-observer reproducibility for classifying the patterns of involvement of 91 and 96%, respectively. Uni- and multivariate analyses demonstrated the adverse influence of (i) a ratio of LFo/BMB > or = 0.1, i.e. three or four nodules/medullary space or > or = 1 nodule + foci of diffuse involvement on EFS (P = 0.03) and (ii) two different histological patterns in the same BMB on EFS (P = 0.004) and OS (P = 0.001). This latter finding was only significant in patients with a high tumour burden and remained significant in multivariate analysis. These results indicate that BMB histology can predict survival of FL patients with a high tumour burden, and may help in defining their treatment. Copyright 2004 Blackwell Publishing Ltd

Entities:  

Mesh:

Year:  2004        PMID: 15257708     DOI: 10.1111/j.1365-2141.2004.05046.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Bone marrow trephine biopsy involvement by lymphoma: pattern of involvement and concordance with flow cytometry, in 10 years from a single institution.

Authors:  M A Cabezas-Quintario; P Gomez; V Yuste-Del Pozo; A L Valencia-Mesa; G Sosa; P Ricard; A I Hijas-Gómez; F Pinedo; M Arguelles
Journal:  Clin Transl Oncol       Date:  2015-08-27       Impact factor: 3.405

Review 2.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

3.  Comparison of Bone Marrow Involvement with Bone Marrow Biopsy and PET-CT and Evaluation of Any Effects on Survival in Patients Diagnosed with Hodgkin and Non-Hodgkin Lymphoma.

Authors:  Mesut Göçer; Erdal Kurtoğlu
Journal:  Indian J Hematol Blood Transfus       Date:  2020-05-04       Impact factor: 0.900

4.  Stromal cell contribution to human follicular lymphoma pathogenesis.

Authors:  Frédéric Mourcin; Céline Pangault; Rada Amin-Ali; Patricia Amé-Thomas; Karin Tarte
Journal:  Front Immunol       Date:  2012-09-05       Impact factor: 7.561

5.  Prognostic value of bone marrow involvement by clonal immunoglobulin gene rearrangements in follicular lymphoma.

Authors:  Ellen Berget; Lars Helgeland; Knut Liseth; Turid Løkeland; Anders Molven; Olav Karsten Vintermyr
Journal:  J Clin Pathol       Date:  2014-09-18       Impact factor: 3.411

6.  Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.

Authors:  Chi Hoon Maeng; Sung Woo Ahn; Seong-Yoon Ryu; Sungjun Han; Young Hyeh Ko; Jun Ho Ji; Won Seog Kim; Seok Jin Kim
Journal:  Korean J Intern Med       Date:  2016-02-22       Impact factor: 2.884

7.  Grading of follicular lymphoma using flow cytometry.

Authors:  Walid A Mourad; Faisal Rawas; Mohamed Shoukri; Abdelghani Tbakhi; Mohamed Al Omari; Asma Tulbah; Fouad Al Dayel
Journal:  Ann Saudi Med       Date:  2006 May-Jun       Impact factor: 1.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.